T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis.
Immunosuppressive therapies are critical in the management of numerous conditions including myasthenia gravis. Mycophenolate mofetil is a widely used, oral immunosuppressive agent that is considered to have few adverse effects compared with similar drugs. We report the case of a patient who developed T-cell lymphoproliferative lesions following long-term treatment with mycophenolate mofetil and prednisone for myasthenia gravis. The lesions resolved following cessation of the treatment. This case highlights a serious complication of a commonly used drug.
Dubal
Dena B
DB
Department of Neurology, University of California at San Francisco, 505 Parnassus Avenue, Box 0114, San Francisco, California 94143, USA.
Mueller
Sabine
S
Ruben
Beth S
BS
Engstrom
John W
JW
Josephson
S Andrew
SA
D000368:Aged; D015415:Biomarkers / Q000032:analysis; D020031:Epstein-Barr Virus Infections / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D005260:Female; D005836:Genitalia, Female / Q000000981:diagnostic imaging / Q000473:pathology; D005881:Gingiva / Q000473:pathology; D005891:Gingivitis / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D009055:Mouth / Q000000981:diagnostic imaging / Q000473:pathology; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000821:virology
D015415:Biomarkers; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D011241:Prednisone